NATO's New Red Line: Hybrid Attacks on Members Will Not Be Tolerated
The US envoy to NATO signals a tougher collective response to cyber, disinformation, and sabotage - a shift with direct implications for multinational boards and risk officers.

Loading the Newsroom
Curating from trusted global sources…
267 briefings · “us”
The US envoy to NATO signals a tougher collective response to cyber, disinformation, and sabotage - a shift with direct implications for multinational boards and risk officers.
Carla Bacon, 69, is the sole caregiver for her bedbound husband while managing medical debt, insurance denials, and a full-time job in Oklahoma.
A misread comment from a Sony DADC executive sparked panic over a 90% collapse, but the actual number is a far smaller decline that changes the physical media timeline.
The federal investigation could delay Tesla's robotaxi launch in Texas and Florida, where the Cybercab is set to pick up passengers without a steering wheel or pedals.
The USTA is doubling creator invites, but on-court disruptions show the tension between viral reach and fan experience.
A $39 cut, a coupon box, and a flagship set that launched in August 2025 already at its lowest price ever.
The OpenAI CEO's reaction to Apple's lawsuit reveals a bigger problem: California's ban on non-competes leaves companies with no choice but to sue after the fact.
The Atlanta Braves added a catcher just days after trimming their roster, a move that could reshape their bench and bullpen management down the stretch.
WIRED's latest briefing ties an agent-led exploit to a massive identity data leak and the US military's new stance on location data, exposing the converging risks for every enterprise adopting AI.
Escalating tensions in the Strait of Hormuz are pushing up crude prices and insurance costs, forcing energy traders and shippers to reassess risk.
Volkswagen reached a labor settlement to shrink its German footprint, but the real test is whether restructuring buys a path forward or just delays the decline.
Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.